Table 4.

Serum Concentrations of gabapentin and buprenorphine from five human subjects after transitioning to from buprenorphine to gabapentin.^*

Subject ID	Gabapentin Concentration (ng/mL)	Buprenorphine Concentration (ng/mL)
1	9464	ND
2	2654	ND
3	ND	ND
4	4038	ND
5	2296	ND

^*100 mg of gabapentin twice a day on day 3 of week 1 followed by increasing doses of gabapentin daily of 200 mg, 400 mg, 600 mg, 800 mg, and 1600 mg though day 7 of week 1. The 1600 mg dose was continued through week 4. buprenorphine dosage was as follows; 4 mg given initially and 4 mg given 30 minutes later on day 1 followed by 12 mg given daily on day 2 through week 2 day 2. The dose was decreased to 8 mg on day 3 and 4 of week 2, 6 mg on days 5–7, 4 mg on week 3 day 1, 2 mg on week 3 days 2–3 and 1 mg on days 4–5 of week 3. Serum samples were collected at the beginning of week 4. ND indicates below the detection limit of 10 ng/mL for both gabapentin and buprenorphine.